ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2046

Serum Immunoglobulin G Targets Citrulline-Containing Immunoglobulin G Peptides in Rheumatoid Arthritis Patients Who Test Positive for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies

Mandar Bawadekar1, Zihao Zheng2, Alan J. Bridges3,4, Michael A. Newton5 and Miriam A. Shelef1,4, 1Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, Madison, WI, 2Departments of Statistics, University of Wisconsin - Madison, Madison, WI, 3Medicine, University of Wisconsin - Madison, Madison, WI, 4William S. Middleton Memorial Veterans Hospital, Madison, WI, 5Departments of Statistics and of Biostatistics and Medical Informatics, University of Wisconsin - Madison, Madison, WI

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: ACPA, Antibody microarray, citrulline and rheumatoid arthritis (RA), Rheumatoid Factor

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Title: Rheumatoid Arthritis – Etiology and Pathogenesis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis patients produce a variety of anti-citrullinated protein antibodies (ACPAs) as well as antibodies that bind homocitrullinated and malondialdehyde-acetaldehyde adducted proteins leading to the theory that rheumatoid arthritis antibodies target a range of post-translationally modified proteins. Further, protein modifications may contribute to the loss of immune tolerance in rheumatoid arthritis. However, most rheumatoid arthritis patients also generate antibodies against immunoglobulin G (IgG), called rheumatoid factor (RF), with a high incidence of co-positivity for RF and anti-cyclic citrullinated peptide (CCP) antibodies. While native proteins can be targeted in rheumatoid arthritis, their citrullinated counterparts are often preferentially targeted. IgG is citrullinated in rheumatoid arthritis, but it is not known if native, homocitrullinated, or citrullinated IgG is preferentially bound by autoantibodies. The purpose of this study is to determine if antibodies in rheumatoid arthritis bind to citrulline-containing, homocitrulline-containing, and/or native IgG peptides.

Methods: A high density peptide array was designed to include every possible 12 amino acid peptide in the constant region of the heavy chain of human IgG1, IgG2, IgG3, and IgG4. Serum from control as well as CCP+RF+, CCP-RF+, CCP+RF-, and CCP-RF- rheumatoid arthritis subjects (n=12) was obtained from our biorepository and subjected to the array. Average raw signal intensity for binding of serum IgM and IgG for each category of rheumatoid arthritis subjects was compared to controls to generate a fold increase value for each peptide. Native and citrulline-containing versions of 3 peptides with very high serum IgG binding and also high homology among IgG isotypes were used to detect serum IgG binding for control and CCP+RF+ rheumatoid arthritis subjects (n=40) by enzyme linked immunosorbent assay (ELISA). ELISA results were compared by t test with p<0.05 considered significant.

Results: RF+ subjects (RF+CCP- and RF+CCP+) demonstrate a small elevation in binding of IgM to many native, homocitrulline-containing, and citrulline-containing peptides of the constant region of IgG1, IgG2, IgG3, and IgG4. Serum from the CCP+RF+ group, and no other rheumatoid arthritis group, demonstrated high IgG binding predominantly to citrulline-containing peptides in the constant region of IgG1, IgG2, IgG3, and IgG4. When measured by ELISA, CCP+RF+ subjects had more IgG binding than controls to only 1 of the 3 native IgG peptides, whereas CCP+RF+ subjects had more IgG binding than controls to all 3 of the citrulline-containing versions of the same IgG peptides. Moreover, for the 1 native peptide with increased binding in CCP+RF+ subjects compared to controls, the binding was 3x higher to the citrulline-containing version of that peptide than the native version.

Conclusion: IgG from CCP+RF+ rheumatoid arthritis patients has high binding to citrulline-containing IgG peptides suggesting that rheumatoid factor of the IgG isotype may be an ACPA. These findings support a unified view of autoantibodies in rheumatoid arthritis and may explain how tolerance is broken against IgG.


Disclosure: M. Bawadekar, None; Z. Zheng, None; A. J. Bridges, None; M. A. Newton, None; M. A. Shelef, None.

To cite this abstract in AMA style:

Bawadekar M, Zheng Z, Bridges AJ, Newton MA, Shelef MA. Serum Immunoglobulin G Targets Citrulline-Containing Immunoglobulin G Peptides in Rheumatoid Arthritis Patients Who Test Positive for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/serum-immunoglobulin-g-targets-citrulline-containing-immunoglobulin-g-peptides-in-rheumatoid-arthritis-patients-who-test-positive-for-rheumatoid-factor-and-anti-cyclic-citrullinated-peptide-antibodies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-immunoglobulin-g-targets-citrulline-containing-immunoglobulin-g-peptides-in-rheumatoid-arthritis-patients-who-test-positive-for-rheumatoid-factor-and-anti-cyclic-citrullinated-peptide-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology